Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05403385 | Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer | PHASE2 | ACTIVE NOT_RECRUITING | 36 | — | — | Aug 26, 2022 | Oct 1, 2025 | Aug 3, 2025 | 21 | United States, Belgium +6 |
Incidence of dose-limiting toxicities
Incidence of adverse events (AEs), serious adverse events, AEs leading to discontinuation, deaths, and clinically significant laboratory abnormalities.
Time from first dose to the date of first documented radiologic progression per RECIST v1.1 or time of death, whichever comes first
| Arm | Type | Description |
|---|---|---|
| Part 1, open label | EXPERIMENTAL | Inupadenant will be given at one or more dose levels to determine the recommended Phase 2 dose (RP2D). |
| Part 2, active treatment | EXPERIMENTAL | Treatment with inupadenant combined with carboplatin and pemetrexed |
| Part 2, placebo | PLACEBO_COMPARATOR | Treatment with matched placebo combined with carboplatin and pemetrexed |
| Name | Type | Description |
|---|---|---|
| inupadenant | DRUG | Adenosine 2a receptor antagonist |
| Placebo | DRUG | matched placebo capsule to inupadenant |
| Carboplatin | DRUG | standard of care chemotherapeutic, alkylating agent |
| Pemetrexed | DRUG | standard of care chemotherapeutic, anti-metabolite |
Inclusion Criteria: * Confirmed diagnosis of metastatic (Stage IV) or locally advanced, unresectable (Stage III) NSCLC of nonsquamous pathology * Measurable disease as defined by RECIST v1.1 * PD-L1 expression status available at or after the time of diagnosis. All levels of expression are eligible...